ciprofol + oliceridine

Ciprofol + oliceridine is a pharmacological combination being investigated for procedural sedation and analgesia, particularly in patients undergoing hysteroscopy. Ciprofol is a novel 2,6-disubstituted phenol derivative that acts as a potent agonist of the Gamma-aminobutyric acid type A (GABA_A) receptor, providing rapid onset and recovery from sedation with a potentially improved safety profile compared to propofol. Oliceridine is a G-protein biased mu-opioid receptor (MOR) agonist designed to provide effective analgesia while minimizing the recruitment of beta-arrestin 2, a pathway associated with typical opioid-related adverse events such as respiratory depression and gastrointestinal dysfunction. The combination is being studied by researchers at the Affiliated Shunde Hospital of Jinan University to optimize anesthetic depth and patient safety during short surgical procedures by leveraging the synergistic effects of a high-potency sedative and a biased opioid analgesic.

Other names

HSK-3486HSK3486HSK 3486TRV-130TRV130TRV 130